Last Week Dermira, Inc. (NASDAQ:DERM) Ratings

May 17, 2018 - By Matthew Richard

Dermira, Inc. (NASDAQ:DERM) Corporate Logo
Big Money Sentiment decreased to 1.27 in 2017 Q4. It has change of 0.76, from 2017Q3’s 2.03. The ratio dropped due to Dermira, Inc. positioning: 16 sold and 35 reduced. 25 funds bought stakes and 40 increased stakes. Investors holded 41.09 million in 2017Q3 but now own 38.81 million shares or 5.56% less.
Tower Research Capital Limited Liability (Trc) holds 1,060 shs or 0% of its capital. Barclays Public Ltd Com reported 0% stake. Millennium Management Llc reported 901,981 shs or 0.03% of all its holdings. Envestnet Asset Mgmt reported 0% of its capital in Dermira, Inc. (NASDAQ:DERM). Landscape Management Ltd reported 0.04% of its capital in Dermira, Inc. (NASDAQ:DERM). Moreover, Ardsley Advisory Prtnrs has 0.03% invested in Dermira, Inc. (NASDAQ:DERM) for 10,000 shs. Abingworth Llp reported 70,000 shs. 37,738 are held by Rhumbline Advisers. Opaleye Mgmt invested in 100,000 shs or 0.89% of the stock. Jennison Associates Limited Liability Co reported 0.03% in Dermira, Inc. (NASDAQ:DERM). Pictet Asset Mgmt has 0.01% invested in Dermira, Inc. (NASDAQ:DERM). California-based Schwab Charles Invest has invested 0% in Dermira, Inc. (NASDAQ:DERM). Teachers Retirement Systems Of The State Of Kentucky holds 0.01% or 34,275 shs. Citadel Advsrs Llc owns 348,491 shs for 0.01% of their capital. Td Asset Mngmt reported 41,615 shs.

Dermira, Inc. registered $1.01 million net activity with 0 insider purchases and 10 insider sales since December 13, 2017. The insider WIGGANS THOMAS G sold 5,000 shs worth $137,566. On Thursday, March 1 Cohen David E sold $15,510 worth of Dermira, Inc. (NASDAQ:DERM) or 600 shs. $499,354 worth of Dermira, Inc. (NASDAQ:DERM) was sold by Griffith Christopher M. on Tuesday, January 2.

Dermira, Inc. (NASDAQ:DERM) Ratings Coverage

A total of 5 analysts rate Dermira (NASDAQ:DERM) as follows: 3 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 60% are bullish. (NASDAQ:DERM) has 9 ratings reports on May 17, 2018 according to StockzIntelligence. On Monday, March 5 the firm earned “Hold” rating by Mizuho. On Thursday, February 22 Cantor Fitzgerald maintained the shares of DERM in report with “Buy” rating. On Tuesday, December 12 the stock of Dermira, Inc. (NASDAQ:DERM) earned “Buy” rating by Mizuho. On Wednesday, January 17 Leerink Swann maintained Dermira, Inc. (NASDAQ:DERM) with “Buy” rating. In Tuesday, March 6 report Guggenheim downgraded the stock to “Neutral” rating. On Friday, February 23 Mizuho maintained the shares of DERM in report with “Buy” rating. On Thursday, May 3 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, December 5 the company was initiated by Guggenheim. Listed here are Dermira, Inc. (NASDAQ:DERM) PTs and latest ratings.

03/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0000 Maintain
06/03/2018 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Downgrade
05/03/2018 Broker: Mizuho Rating: Hold Downgrade
05/03/2018 Broker: Cowen & Co Rating: Buy New Target: $25.0
23/02/2018 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
22/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
17/01/2018 Broker: Leerink Swann Rating: Buy New Target: $48.0 Maintain
12/12/2017 Broker: Mizuho Rating: Buy New Target: $39.0 Maintain
05/12/2017 Broker: Guggenheim Rating: Buy Initiate

DERM reached $11.13 during the last trading session after $0.38 change.Dermira, Inc. has volume of 165,295 shares. Since May 17, 2017 DERM has declined 77.97% and is downtrending. DERM underperformed by 89.52% the S&P500.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States.The firm is worth $465.77 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.Currently it has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

For more Dermira, Inc. (NASDAQ:DERM) news announced recently go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Christopher Horan Joins Dermira as Chief Technical Operations Officer” announced on April 19, 2018, “Dermira to Present at Deutsche Bank 43rd Annual Healthcare Conference” on May 01, 2018, “Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update” with a publish date: May 03, 2018, “Dermira and Cameran Eubanks Team Up to Raise Awareness of Excessive Sweating for the 15 Million People Living …” and the last “Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” with publication date: May 08, 2018.

Dermira, Inc. (NASDAQ:DERM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.